Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Rana McKay, MD
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Ignacio Duran, MD
Sandy Srinivas, MD
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Ritu Salani, MD, MBA
Nicoletta Colombo, MD
Innovations in Oncology Learning Center From Guidelines to Practice: Gynecologic Cancer
Susana Campos, MD, MPH
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Wenxin Xu, MD
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Guideline Updates for ADT: Best Practices for Treating Advanced Prostate Cancer
Tanya Dorff, MD
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.